Cost-efficient and easy to perform PCR-based assay to identify MET exon 14 skipping in formalin-fixed paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) samples

Odharnaith O’Brien; Mark C. Wright; Cathal O’Brien; Orla Geoghegan; Niamh Leonard; Siobhan Nicholson; Sinéad Cuffe; Aurelie Fabre; Wolfram Jochum; Markus Joerger; Steven G. Gray; Stephen P. Finn

doi:10.3390/diagnostics9010013

Cost-efficient and easy to perform PCR-based assay to identify MET exon 14 skipping in formalin-fixed paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) samples

Odharnaith O’Brien, Mark C. Wright, Cathal O’Brien, Orla Geoghegan, Niamh Leonard, Siobhan Nicholson, Sinéad Cuffe, Aurelie Fabre, Wolfram Jochum, Markus Joerger, Steven G. Gray, Stephen P. Finn

Research output: Contribution to journal › Article › peer-review

Abstract

MET is a receptor tyrosine kinase (RTK) that plays important roles in carcinogenesis. Despite being frequently overexpressed in cancer, clinical responses to targeting this receptor have been limited. Recently novel splicing mutations involving the loss of exon 14 (called METex14 skipping) have emerged as potential biomarkers to predict for responsiveness to targeted therapies with Met inhibitors in non-small cell lung cancer (NSCLC). Currently, the diverse genomic alterations responsible for METex14 skipping pose a challenge for routine clinical diagnostic testing. In this report, we examine three different methodologies to detect METex14 and assess their potential utility for use as a diagnostic assay for both the identification of METex14 and intra-tumoural distribution in NSCLC.

Original language	English
Article number	13
Journal	Diagnostics
Volume	9
Issue number	1
DOIs	https://doi.org/10.3390/diagnostics9010013
Publication status	Published - 1 Mar 2019
Externally published	Yes

Keywords

Diagnostic assay
Met exon 14 skipping
Next generation sequencing
PCR
RNA hybridisation

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/diagnostics9010013Licence: CC BY

https://arrow.tudublin.ie/scschbioart/205Licence: CC BY

Cite this

O’Brien, O., Wright, M. C., O’Brien, C., Geoghegan, O., Leonard, N., Nicholson, S., Cuffe, S., Fabre, A., Jochum, W., Joerger, M., Gray, S. G., & Finn, S. P. (2019). Cost-efficient and easy to perform PCR-based assay to identify MET exon 14 skipping in formalin-fixed paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) samples. Diagnostics, 9(1), Article 13. https://doi.org/10.3390/diagnostics9010013

@article{8ebd88ef206d41bcb6a018872fa48e6b,

title = "Cost-efficient and easy to perform PCR-based assay to identify MET exon 14 skipping in formalin-fixed paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) samples",

abstract = "MET is a receptor tyrosine kinase (RTK) that plays important roles in carcinogenesis. Despite being frequently overexpressed in cancer, clinical responses to targeting this receptor have been limited. Recently novel splicing mutations involving the loss of exon 14 (called METex14 skipping) have emerged as potential biomarkers to predict for responsiveness to targeted therapies with Met inhibitors in non-small cell lung cancer (NSCLC). Currently, the diverse genomic alterations responsible for METex14 skipping pose a challenge for routine clinical diagnostic testing. In this report, we examine three different methodologies to detect METex14 and assess their potential utility for use as a diagnostic assay for both the identification of METex14 and intra-tumoural distribution in NSCLC.",

keywords = "Diagnostic assay, Met exon 14 skipping, Next generation sequencing, PCR, RNA hybridisation",

author = "Odharnaith O{\textquoteright}Brien and Wright, \{Mark C.\} and Cathal O{\textquoteright}Brien and Orla Geoghegan and Niamh Leonard and Siobhan Nicholson and Sin{\'e}ad Cuffe and Aurelie Fabre and Wolfram Jochum and Markus Joerger and Gray, \{Steven G.\} and Finn, \{Stephen P.\}",

note = "Publisher Copyright: {\textcopyright} 2019 by the authors.",

year = "2019",

month = mar,

day = "1",

doi = "10.3390/diagnostics9010013",

language = "English",

volume = "9",

journal = "Diagnostics",

issn = "2075-4418",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "1",

}

O’Brien, O, Wright, MC, O’Brien, C, Geoghegan, O, Leonard, N, Nicholson, S, Cuffe, S, Fabre, A, Jochum, W, Joerger, M, Gray, SG & Finn, SP 2019, 'Cost-efficient and easy to perform PCR-based assay to identify MET exon 14 skipping in formalin-fixed paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) samples', Diagnostics, vol. 9, no. 1, 13. https://doi.org/10.3390/diagnostics9010013

TY - JOUR

T1 - Cost-efficient and easy to perform PCR-based assay to identify MET exon 14 skipping in formalin-fixed paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) samples

AU - O’Brien, Odharnaith

AU - Wright, Mark C.

AU - O’Brien, Cathal

AU - Geoghegan, Orla

AU - Leonard, Niamh

AU - Nicholson, Siobhan

AU - Cuffe, Sinéad

AU - Fabre, Aurelie

AU - Jochum, Wolfram

AU - Joerger, Markus

AU - Gray, Steven G.

AU - Finn, Stephen P.

PY - 2019/3/1

Y1 - 2019/3/1

N2 - MET is a receptor tyrosine kinase (RTK) that plays important roles in carcinogenesis. Despite being frequently overexpressed in cancer, clinical responses to targeting this receptor have been limited. Recently novel splicing mutations involving the loss of exon 14 (called METex14 skipping) have emerged as potential biomarkers to predict for responsiveness to targeted therapies with Met inhibitors in non-small cell lung cancer (NSCLC). Currently, the diverse genomic alterations responsible for METex14 skipping pose a challenge for routine clinical diagnostic testing. In this report, we examine three different methodologies to detect METex14 and assess their potential utility for use as a diagnostic assay for both the identification of METex14 and intra-tumoural distribution in NSCLC.

AB - MET is a receptor tyrosine kinase (RTK) that plays important roles in carcinogenesis. Despite being frequently overexpressed in cancer, clinical responses to targeting this receptor have been limited. Recently novel splicing mutations involving the loss of exon 14 (called METex14 skipping) have emerged as potential biomarkers to predict for responsiveness to targeted therapies with Met inhibitors in non-small cell lung cancer (NSCLC). Currently, the diverse genomic alterations responsible for METex14 skipping pose a challenge for routine clinical diagnostic testing. In this report, we examine three different methodologies to detect METex14 and assess their potential utility for use as a diagnostic assay for both the identification of METex14 and intra-tumoural distribution in NSCLC.

KW - Diagnostic assay

KW - Met exon 14 skipping

KW - Next generation sequencing

KW - PCR

KW - RNA hybridisation

UR - https://www.scopus.com/pages/publications/85066420291

U2 - 10.3390/diagnostics9010013

DO - 10.3390/diagnostics9010013

M3 - Article

SN - 2075-4418

VL - 9

JO - Diagnostics

JF - Diagnostics

IS - 1

M1 - 13

ER -

Cost-efficient and easy to perform PCR-based assay to identify MET exon 14 skipping in formalin-fixed paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) samples

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this